Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chava Perry

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Leukemia Research|February 26, 2014
Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrationsYair Herishanu, Sigi Kay, Erel Joffe, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 18, 2012
Divergence in CD19-mediated signaling unfolds intraclonal diversity in chronic lymphocytic leukemia, which correlates with disease progressionYair Herishanu, Sigi Kay, Nili Dezorella, et al.
European Journal of Haematology|September 26, 2021
Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cellsOfrat Beyar-Katz, Nino Kikozashvili, Yael Bar On, et al.
American Journal of Hematology|June 19, 2019
Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter studyChava Perry, Sharon Ben Barouch, Neta Goldschmidt, et al.
European Journal of Haematology|October 17, 2022
The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter studyLiat Shargian, Odelia Amit, Hanna Bernstine, et al.
Annals of Hematology|June 22, 2022
Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experienceOfrat Beyar-Katz, Chava Perry, Yael Bar On, et al.
Journal of Personalized Medicine|August 27, 2021
Feasibly of CD24/CD11b as a Screening Test for Hematological MalignanciesShiran Shapira, Dina Kazanov, Fatin Mdah, et al.
Frontiers in Immunology|November 16, 2020
Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in MiceAlbert Kolomansky, Irit Kaye, Nathalie Ben-Califa, et al.
Haematologica|February 12, 2026
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot studyGil Fridberg, Odelia Amit, Yehonathan Sherf, et al.
Hematological Oncology|November 21, 2024
Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell LymphomaMeirav Kedmi, Elena Ribakovsy, Ohad Benjamini, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Leukemia Research|February 26, 2014
Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrationsYair Herishanu, Sigi Kay, Erel Joffe, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 18, 2012
Divergence in CD19-mediated signaling unfolds intraclonal diversity in chronic lymphocytic leukemia, which correlates with disease progressionYair Herishanu, Sigi Kay, Nili Dezorella, et al.
European Journal of Haematology|September 26, 2021
Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cellsOfrat Beyar-Katz, Nino Kikozashvili, Yael Bar On, et al.
American Journal of Hematology|June 19, 2019
Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter studyChava Perry, Sharon Ben Barouch, Neta Goldschmidt, et al.
European Journal of Haematology|October 17, 2022
The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter studyLiat Shargian, Odelia Amit, Hanna Bernstine, et al.
Annals of Hematology|June 22, 2022
Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experienceOfrat Beyar-Katz, Chava Perry, Yael Bar On, et al.
Journal of Personalized Medicine|August 27, 2021
Feasibly of CD24/CD11b as a Screening Test for Hematological MalignanciesShiran Shapira, Dina Kazanov, Fatin Mdah, et al.
Frontiers in Immunology|November 16, 2020
Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in MiceAlbert Kolomansky, Irit Kaye, Nathalie Ben-Califa, et al.
Haematologica|February 12, 2026
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot studyGil Fridberg, Odelia Amit, Yehonathan Sherf, et al.
Hematological Oncology|November 21, 2024
Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell LymphomaMeirav Kedmi, Elena Ribakovsy, Ohad Benjamini, et al.
Pageof 8